[1] Ginsberg HS. Adenoviruses. Am J Clin Pathol. 1972;57:771-776.

[2] Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med.


Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003;92:1098-1106.

Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Orden MR, Kholova I et al. Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation. 2005;20;112:3937-3946. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P et al. beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther. 1998;9:1769-1774.

Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA. 1997;94: 3352-3356.

Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309-319. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology. 2000;268:382-390. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBOJ. 1997;16:2294-2306.

Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation. 2000;102:2262-2268.

Rutanen J, Turunen AM, Teittinen M, Rissanen TT, Heikura T, Koponen JK et al. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Ther. 2005;12:980-987.

Leppanen O, Rutanen J, Hiltunen MO, Rissanen TT, Turunen MP, Sjoblom T et al. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation. 2004;109:1140-1146.

Laitinen M, Mäkinen K, Manninen H, Matsi P, Kossila M, Agrawal RS et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther. 1998;9:1481-1486.

Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med. 2004;6 Suppl 1:S164-S171.

Nalbantoglu J, Pari G, Karpati G, Holland PC. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther. 1999;10:1009-1019. Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med. 2002;4:371-380.

Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivela A et al. Adenoviral Catheter-Mediated Intramyocardial Gene Transfer Using the Mature Form of Vascular Endothelial Growth Factor -D Induces Transmural Angiogenesis in Porcine Heart. Circulation. 2004;109: 1029-1035.

Poliakova L, Kovesdi I, Wang X, Capogrossi MC, Talan M. Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle. J Thorac Cardiovasc Surg. 1999;118:339-347.

Thirion C, Lochmuller H, Ruzsics Z, Boelhauve M, Konig C, Thedieck C et al. Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum Gene Ther. 2006;17:193-205.

Sinnreich M, Shaw CA, Pari G, Nalbantoglu J, Holland PC, Karpati G. Localization of coxsackie virus and adenovirus receptor (CAR) in normal and regenerating human muscle. Neuromuscul Disord. 2005;15:541-548.

[21] Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003;107: 2677-2683.

[22] Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E et al. Increased Vascularity Detected by Digital Subtraction Angiography after VEGF Gene Transfer to Human Lower Limb Artery: A Randomized, Placebo-Controlled, Double-Blinded Phase II Study. Mol Ther. 2002;6:127-133.

[23] Wirth T, Hedman M, Mäkinen K, Manninen H, Immonen A, Vapalahti M et al. Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy. Current Drug Safety. 2006;1: 253-257.

[24] Chen P, Kovesdi I, Bruder JT. Effective repeat administration with adenovirus vectors to the muscle. Gene Ther. 2000;7:587-595.

[25] Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 2005;12 Suppl 1:S18-27.:S18-S27.

[26] Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002;21:1939-1947.

[27] Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, Salvi A et al. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther. 2003;7:450-459.

[28] Ylä-Herttuala, S., Rissanen, T., Vajanto, I., Hartikainen, J. Vascular endothelial growth factors -biology and current status of clinical applications in cardiovascular medicine. Journal of the American Cardiology of College. 2007. Ref Type: In Press

[29] Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther. 2005;5:323-331.

[30] Mangeat B, Trono D. Lentiviral vectors and antiretroviral intrinsic immunity. Hum Gene Ther. 2005;16:913-920.

[31] Mäkinen, K., Laitinen, M., Manninen, H., Matsi, P., Alhava, E., Ylä-Herttuala, S. Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA. Circulation 100(18), I-770. 2-11-1999.

[32] Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of vegf(121) improves lower-extremity endothelial function and flow reserve. Circulation. 2001;104:753-755.

[33] Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, Pak R et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol. 2002;90:512-516.

[34] Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J et al. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. 2002;13:65-100.

[35] Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006.

[36] Rajagopalan S, Mohler ER, III, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933-1938.

[37] Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I et al. Fibroblast growth factor-4 induces vascular permeability, angiogenesis, and arteriogenesis in a rabbit hind limb ischemia model. FASEB J. 2003;17:100-102.

Was this article helpful?

0 0

Post a comment